What is the current bottleneck in mapping molecular interaction networks?
Michael A Skinnider, Katja Luck, M Shahid Mukhtar, Martin Garrido-Rodriguez, Julio Saez-Rodriguez, Jolanda van Leeuwen, Pedro Beltrao, Anne-Ruxandra Carvunis, Mikko Taipale, Andrew Emili, Martha L Bulyk, Nevan J Krogan
- PMID: 40403700
- DOI: 10.1016/j.cels.2025.101295
No abstract available
Conflict of interest statement
Declaration of interests A.-R.C. is a member of the scientific advisory board for ProFound Therapeutics. J.S.-R. reports in the last 3 years funding from GSK and Pfizer and fees/honoraria from Travere Therapeutics, STADApharm, Astex, Pfizer, Owkin, Moderna, and Grunenthal. M.A.S. is a member of the Rutgers Cancer Institute of New Jersey (RCINJ). The Krogan laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. N.J.K. has a financially compensated consulting agreement with Maze Therapeutics. He is the president and is on the board of directors of Rezo Therapeutics, and he is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and GEn1E Lifesciences.